The general public's knowledge of biotech has increased and improved exponentially following the pandemic. That is perhaps one of the positives we can take from Covid-19: Pfizer, Moderna, BionTech and AstraZeneca are all now household names.
Just as the public's knowledge has improved, so too have investors woken up to the opportunities and possibilities investing in biotechnology could bring. Before Covid-19 put a petri-dish around the globe, the biotechnology industry was benefitting from increasing global population growth and the inexorable growth of the middle class in developing countries. Life expectancy was also increasing worldwide. However, we have to be careful what we wish for: in the era of the "I", the selfie and the global desire for a lifestyle of instant gratification, that too leads to a concerning incre...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
